Semi-chronic increase in striatal level of 3,4-dihydroxyphenylacetaldehyde does not result in alteration of nigrostriatal dopaminergic neurones
Article first published online: 6 JAN 2004
Copyright © 2004 Wiley-Liss, Inc.
Journal of Neuroscience Research
Volume 75, Issue 3, pages 429–435, 1 February 2004
How to Cite
Legros, H., Janin, F., Dourmap, N., Bonnet, J.-J. and Costentin, J. (2004), Semi-chronic increase in striatal level of 3,4-dihydroxyphenylacetaldehyde does not result in alteration of nigrostriatal dopaminergic neurones. J. Neurosci. Res., 75: 429–435. doi: 10.1002/jnr.10880
- Issue published online: 20 JAN 2004
- Article first published online: 6 JAN 2004
- Manuscript Accepted: 29 OCT 2003
- Manuscript Revised: 27 OCT 2003
- Manuscript Received: 8 APR 2003
- Direction de la Recherche et de la Technologie. Grant Number: 97-187
- brain aldehyde dehydrogenase;
- in vivo;
This work was carried out to evaluate the potential in vivo toxicity of 3,4-dihydroxyphenylacetaldehyde (DOPAL), an aldehyde formed from dopamine by monoamine oxidase (MAO) that is oxidised mainly to 3,4-dihydroxyphenylacetic acid (DOPAC) by brain aldehyde dehydrogenases (ALDH). In this study, male Sprague-Dawley rats were treated with levodopa (L-dopa)-benserazide, which increases DOPAL production by MAO, and disulfiram, an irreversible inhibitor of ALDH, which reduces the formation of DOPAC from DOPAL. An acute systemic intraperitoneal (i.p.) injection of 100 mg/kg disulfiram and L-dopa-benserazide (100 mg/kg + 25 mg/kg, 24 hr later) significantly increased DOPAL striatal level. A 30-day treatment with disulfiram (100 mg/kg i.p., once every 2 days) and L-dopa-benserazide (100 mg/kg + 25 mg/kg, two times/day) did not affect either indexes used to assess integrity of the nigrostriatal dopaminergic neurones (i.e., the striatal content in dopamine and binding to the vesicular monoamine transporter on striatal membranes). These results do not evidence any deleterious effect of DOPAL and argue against toxicity of L-dopa therapy. © 2004 Wiley-Liss, Inc.